NervGen Pharma Corp. (NGEN.V)
| Previous Close | 1.9900 |
| Open | 2.0100 |
| Bid | 1.9900 x 0 |
| Ask | 2.0300 x 0 |
| Day's Range | 1.9800 - 2.0300 |
| 52 Week Range | 1.5200 - 3.3300 |
| Volume | |
| Avg. Volume | 44,235 |
| Market Cap | 93.002M |
| Beta (5Y Monthly) | 1.67 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - May 31, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that the Company has granted 180,000 incentive stock options to a director exercisable at a price of $2.08 per share for a period of five years with vesting that is either time or performance based. All ...
- Newsfile
NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)
Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class
- Newsfile
NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results
Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical ...
